case_images: PMC11301820_01
case_images: Thoracic spine images on admission. (a-d) Magnetic resonance imaging of sagittal section of the thoracic spine (a) T1-weighted image, (b) T2-weighted image, (c) short-tau inversion recovery [STIR] image, and (d) T1-weighted image with contrast enhancement. An intradural extramedullary mass is seen at the T9-T10 level. (e-g) MRI of the axial section of the thoracic spine (e) T1-weighted image, (f) T2-weighted image, and (g) T1-weighted image with contrast enhancement). The mass can be seen to compress the spinal cord to the right. (h) Thoracic computed tomography scan. The mass does not have any calcification.
case_images: SNI-15-250-g001.jpg
case_images: PMC11301820_01_SNI-15-250-g001.jpg
case_images: F1
case_images: T10 sensory level, and bladder/bowel dysfunction. The thoracic MRI revealed an intradural extramedullary cephalad/caudad 15 mm well-defined T9-T10 lesion that markedly compressed to the cord to the left side of the spinal canal; it was hypointense on T1-WI, hyperintense on T2-WI, and markedly enhanced with contrast [Figure 1]. The accompanying non-contrast computed tomography (CT) showed no tumor calcification [Figure 1].
case_images: Pathological examinations. (a) Hematoxylin-Eosin (HE) staining weakly magnified (x 40). (b) HE staining strongly magnified (x400). c-g: Immunohistology staining (c) S100 [positive], (d) HMB45 [positive], (e) PgR [negative], (f) EMA [difficult to determine], (g) Melan A [positive], (h) Fontana Masson, and (i) Berlin blue.
case_images: SNI-15-250-g002.jpg
case_images: PMC11301820_01_SNI-15-250-g002.jpg
case_images: F2
case_images: The histopathological diagnosis was consistent with MMNST [Figure 2].
case_images: Contrast-enhanced thoracic magnetic resonance imaging 1 year after surgery. (a) Sagittal section and (b) axial section. No tumor recurrence can be observed.
case_images: SNI-15-250-g003.jpg
case_images: PMC11301820_01_SNI-15-250-g003.jpg
case_images: F3
case_images: As the systemic metastatic work-up was negative, no further adjuvant therapy was warranted [Figure 3]. Notably, however, the patient continues to be closely followed for the risk of tumor recurrence [Figure 3].